Underpriced Stock: Menlo Therapeutics Inc. (MNLO) Undervalued by 77.79%

    Publicly-traded company Menlo Therapeutics Inc. (NASDAQ:MNLO) had a closing price of $3.96 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $17.83, this means that the stock is underpriced by 77.79%. In the past 52 weeks the company’s stock price has moved within the range of $2.69 to $9.03.

    This particular stock’s 5-day moving average is 3.90, its 20-day moving average is 4.49 and its 100-day moving average is 4.47. Menlo Therapeutics Inc. (MNLO) currently has 22.95M shares outstanding, which means that its market capitalization is $90.88M.

    The Details: Menlo Therapeutics Inc. (MNLO) Financial Health

    We can also find the company’s Return on Assets, which is a percentage that shows us how well a company uses its current assets to make a profit. The larger the score, the better. At the moment, Menlo Therapeutics Inc. Return on Assets is -58.50%.

    What Does Wall Street Say about Company?

    When considering a stock buy, many investors seek to know what Wall Street analysts are saying about the company – by looking at the average analyst rating, for example. At the moment, the average analyst rating for MNLO is Buy. Out of 6 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 1 rated it hold, and 5 rated it a Buy.

    Understanding Profitability at Menlo Therapeutics Inc. (MNLO)

    A smart way of assessing a company’s profitability is by checking out its latest Earnings per Share (EPS). In the most recent financial results released by Menlo Therapeutics Inc., for the quarter ending on 12/2019, the company posted EPS of -0.83. The average estimate of Wall Street analysts had projected -0.81.

    Wall Street analysts, on average, are forecasting the company’s EPS to be -0.83, compared to -0.76 reported in the same quarter last year.